FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110853494> ?p ?o ?g. }

• W2110853494 endingPage "576" @default.
• W2110853494 startingPage "569" @default.
• W2110853494 abstract "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas. Response was assessed following two courses of therapy at the MTD. Temozolomide was administered to cohorts of patients at doses of 100, 125, 160, or 200 mg/m2 on days 1-5, along with 90 mg/m2 lomustine on day 1. Two courses of lomustine/temozolomide were given prior to radiation therapy (RT) and up to six courses were administered afterward. Thirty-two patients were enrolled. Dose-limiting myelosuppression was seen in two of three patients enrolled at the 200 mg/m2 dose level. One of 14 patients in the expanded MTD cohort (160 mg/m2) experienced dose-limiting thrombocytopenia. After two courses at the MTD, one patient with a 5-mm enhancing nodule postoperatively had a complete response, one patient with a large residual temporal lobe glioblastoma had a partial response, and eight patients had stable disease. Several patients developed transient radiographic worsening after completing RT. Median 1- and 2-year overall survivals at the MTD were 60% ± 13% and 40% ± 13% with a median of 17.6 months. Thirteen of 20 patients (65%) who underwent MRI scans within 6 months prior to death developed metastatic disease. In conclusion, when administered with 90 mg/m2 lomustine on day 1, the MTD of temozolomide is 160 mg/m2/day × 5. Radiographic changes following RT make determination of early tumor progression difficult. Metastatic disease is common prior to death." @default.
• W2110853494 created "2016-06-24" @default.
• W2110853494 creator A5001092978 @default.
• W2110853494 creator A5021851526 @default.
• W2110853494 creator A5023318870 @default.
• W2110853494 creator A5026714103 @default.
• W2110853494 creator A5027468886 @default.
• W2110853494 creator A5045068097 @default.
• W2110853494 creator A5046264008 @default.
• W2110853494 creator A5066484657 @default.
• W2110853494 creator A5068359755 @default.
• W2110853494 creator A5080784534 @default.
• W2110853494 date "2008-08-01" @default.
• W2110853494 modified "2023-10-12" @default.
• W2110853494 title "A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood" @default.
• W2110853494 cites W1884303117 @default.
• W2110853494 cites W1999528431 @default.
• W2110853494 cites W2007131804 @default.
• W2110853494 cites W2015653791 @default.
• W2110853494 cites W2017754841 @default.
• W2110853494 cites W2021889101 @default.
• W2110853494 cites W2023824576 @default.
• W2110853494 cites W2034200080 @default.
• W2110853494 cites W2044325621 @default.
• W2110853494 cites W2044337620 @default.
• W2110853494 cites W2054172055 @default.
• W2110853494 cites W2070945600 @default.
• W2110853494 cites W2079786467 @default.
• W2110853494 cites W2087029093 @default.
• W2110853494 cites W2096287682 @default.
• W2110853494 cites W2103594288 @default.
• W2110853494 cites W2104245348 @default.
• W2110853494 cites W2104291790 @default.
• W2110853494 cites W2113012900 @default.
• W2110853494 cites W2116140910 @default.
• W2110853494 cites W2123133319 @default.
• W2110853494 cites W2134644359 @default.
• W2110853494 cites W2137832651 @default.
• W2110853494 cites W2156976216 @default.
• W2110853494 cites W2167288010 @default.
• W2110853494 cites W2365629726 @default.
• W2110853494 cites W4293241248 @default.
• W2110853494 doi "https://doi.org/10.1215/15228517-2008-019" @default.
• W2110853494 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2666230" @default.
• W2110853494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18497327" @default.
• W2110853494 hasPublicationYear "2008" @default.
• W2110853494 type Work @default.
• W2110853494 sameAs 2110853494 @default.
• W2110853494 citedByCount "25" @default.
• W2110853494 countsByYear W21108534942012 @default.
• W2110853494 countsByYear W21108534942013 @default.
• W2110853494 countsByYear W21108534942014 @default.
• W2110853494 countsByYear W21108534942016 @default.
• W2110853494 countsByYear W21108534942017 @default.
• W2110853494 countsByYear W21108534942020 @default.
• W2110853494 countsByYear W21108534942022 @default.
• W2110853494 crossrefType "journal-article" @default.
• W2110853494 hasAuthorship W2110853494A5001092978 @default.
• W2110853494 hasAuthorship W2110853494A5021851526 @default.
• W2110853494 hasAuthorship W2110853494A5023318870 @default.
• W2110853494 hasAuthorship W2110853494A5026714103 @default.
• W2110853494 hasAuthorship W2110853494A5027468886 @default.
• W2110853494 hasAuthorship W2110853494A5045068097 @default.
• W2110853494 hasAuthorship W2110853494A5046264008 @default.
• W2110853494 hasAuthorship W2110853494A5066484657 @default.
• W2110853494 hasAuthorship W2110853494A5068359755 @default.
• W2110853494 hasAuthorship W2110853494A5080784534 @default.
• W2110853494 hasBestOaLocation W21108534941 @default.
• W2110853494 hasConcept C126322002 @default.
• W2110853494 hasConcept C141071460 @default.
• W2110853494 hasConcept C2776694085 @default.
• W2110853494 hasConcept C2776755627 @default.
• W2110853494 hasConcept C2777389519 @default.
• W2110853494 hasConcept C2779429289 @default.
• W2110853494 hasConcept C2779434656 @default.
• W2110853494 hasConcept C31760486 @default.
• W2110853494 hasConcept C71924100 @default.
• W2110853494 hasConceptScore W2110853494C126322002 @default.
• W2110853494 hasConceptScore W2110853494C141071460 @default.
• W2110853494 hasConceptScore W2110853494C2776694085 @default.
• W2110853494 hasConceptScore W2110853494C2776755627 @default.
• W2110853494 hasConceptScore W2110853494C2777389519 @default.
• W2110853494 hasConceptScore W2110853494C2779429289 @default.
• W2110853494 hasConceptScore W2110853494C2779434656 @default.
• W2110853494 hasConceptScore W2110853494C31760486 @default.
• W2110853494 hasConceptScore W2110853494C71924100 @default.
• W2110853494 hasIssue "4" @default.
• W2110853494 hasLocation W21108534941 @default.
• W2110853494 hasLocation W21108534942 @default.
• W2110853494 hasLocation W21108534943 @default.
• W2110853494 hasLocation W21108534944 @default.
• W2110853494 hasOpenAccess W2110853494 @default.
• W2110853494 hasPrimaryLocation W21108534941 @default.
• W2110853494 hasRelatedWork W1509193935 @default.
• W2110853494 hasRelatedWork W1764138133 @default.
• W2110853494 hasRelatedWork W2017695919 @default.
• W2110853494 hasRelatedWork W2031376430 @default.
• W2110853494 hasRelatedWork W2078219238 @default.

• next